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Abstract
Background: Clinically node negative HNSCC patients have a risk ranging
between 18 and 45% of occult metastases, making prophylactic irradiation
mandatory. Selective irradiation of nodal target volume based on international
guidelines is practice. Anyway, about half the tumours lying in an anatomical
subsite known to potentially drain bilaterally effectively do so, leading to
unnecessary large volume irradiation. Moreover, 15% of the tumours show
drainage outside of predicted basin, increasing the risk for potential geographical
misses. Three-dimensional SPECT/CT lymphoscintigraphy (LS) of sentinel
node(s) may help to individualize nodal target volume selection. This prospective
phase I study explores its feasibility and the dosimetric impact.Methods: Ten cN0
HNSCC patients eligible for definitive radiotherapy were imaged with SPECT/
CT after <sup>99m</sup>Tc nanocolloid injection around the tumour. The neck
levels containing up to four hottest nodes were identified and selected for p...
Document type : Article de périodique (Journal article)
Référence bibliographique
Daisne, Jean-François ; Installé, Johanne ; Bihin, Benoît ; Laloux, Marc ; Vander Borght, Thierry ;
et. al. SPECT/CT lymphoscintigraphy of sentinel node(s) for superselective prophylactic irradiation
of the neck in cN0 head and neck cancer patients: A prospective phase I feasibility study.  In:
Radiation Oncology, Vol. 9, no. 1 (2014)
DOI : 10.1186/1748-717X-9-121
RESEARCH Open Access
SPECT/CT lymphoscintigraphy of sentinel node(s)
for superselective prophylactic irradiation of the
neck in cN0 head and neck cancer patients: a
prospective phase I feasibility study
Jean-François Daisne1,2*, Johanne Installé3, Benoît Bihin2,4,5, Marc Laloux6, Thierry Vander Borght2,7,
Isabelle Mathieu3 and Georges Lawson2,8
Abstract
Background: Clinically node negative HNSCC patients have a risk ranging between 18 and 45% of occult metastases,
making prophylactic irradiation mandatory. Selective irradiation of nodal target volume based on international
guidelines is practice. Anyway, about half the tumours lying in an anatomical subsite known to potentially drain
bilaterally effectively do so, leading to unnecessary large volume irradiation. Moreover, 15% of the tumours show
drainage outside of predicted basin, increasing the risk for potential geographical misses. Three-dimensional
SPECT/CT lymphoscintigraphy (LS) of sentinel node(s) may help to individualize nodal target volume selection.
This prospective phase I study explores its feasibility and the dosimetric impact.
Methods: Ten cN0 HNSCC patients eligible for definitive radiotherapy were imaged with SPECT/CT after 99mTc
nanocolloid injection around the tumour. The neck levels containing up to four hottest nodes were identified
and selected for prophylactic irradiation (CTVn-LS) by volumetric modulated arc therapy. A comparative virtual
planning was performed with volumes selected according to international guidelines (CTVn-IG).
Results: Migration was observed in all patients (one with gamma probe only). 2.9 sentinel nodes were detected
per patient on average. In some patients, accurate localization was difficult when not using thermoplastic mask
for SPECT/CT. CTVn-LS was totally encompassed by CTVn-IG in all patients but one (unpredicted drainage in
retropharyngeal level). On average, CTVn-LS and related planning target volumes were two times smaller than
IG ones. This led to significant dose decrease in identified organs at risk as well as remaining volume at risk.
Conclusions: SPECT/CT LS is a promising tool to individualize prophylactic node CTV in cN0 HNSCC patients
eligible for definitive radiotherapy. Oncological safety must be confirmed by ongoing phase II study.
Keywords: Head and neck cancer, Sentinel node, SPECT/CT, Individualized radiotherapy, Target volume selection
Background
Surgery and radiotherapy (RT) are the two treatment
cornerstones of non-metastatic Head and Neck Squamous
Cell Carcinoma (HNSCC). Both modalities have the same
treatment philosophy with ultimate goals being cure
and restoration of Quality of Life (QoL). These goals are
reflected by the therapeutic ratio (i.e. cure rate divided
by side effects rate). Both modern surgery and RT aim
at improving this ratio by maximizing cure rate and
minimizing side effects probability.
In RT, major technical improvements like Three-
Dimensional Conformal Radiation Therapy (3D-CRT) and
Intensity-Modulated Radiation Therapy (IMRT) have al-
lowed to better conform the dose delivered to the target
volumes (TV) while reducing the high doses delivered
to Organs at Risk (OAR) and hence, reducing the late
toxicity of the treatments compared to treatments with
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large 2D fields [1]. The accurate selection and definition
of the different TV is of utmost importance to maximize
the therapeutic ratio when using these highly selective RT
techniques. It is particularly true in the head and neck
region where lymph drainage is intense with a high in-
cidence of nodal metastases, making irradiation of neck
nodes mandatory for most tumours.
The recognition of cancer nodal spread at diagnosis is
essential for the prognosis and the extent of nodal surgery
or the definition of radiotherapy volumes. Different imaging
methods are presently used like Computed Tomography
(CT), Ultrasonography (US) without or with Fine Needle
Aspiration Cytology (FNAC), and to a lesser extent Mag-
netic Resonance Imaging (MRI) and/or combined Positron
Emission and Computed Tomographies with 18-Fluoro-
Deoxy-Glucose (FDG-PET/CT). Their sensitivity and speci-
ficity ranges lay roughly between 40 and 100%, being highly
dependent on the size of the nodes [2]. Indeed, for nodes
showing a diameter smaller or equal to 10 mm in the short
axis or showing no central necrosis, no imaging modality is
reliable enough to detect tumour deposits, and patients are
deemed to be clinically free of nodes (cN0). Anyway, the
risk for occult metastasis is still significant, ranging between
18 and 45% in the most recent surgical series exploring the
role of sentinel lymph nodes (SLN) mapping in oral cavity,
oropharyngeal or laryngo-hypopharyngeal HNSCC [3-13].
These figures preclude cN0 HNSCC patients from a simple
watchful waiting attitude. The selection and definition of
the predicted drainage nodal basins based on primary
tumour location are now well documented by surgeons and
pathologists [14] and coded in RT language [15], allowing
their (most of the time bilateral) selective treatment by
either surgical removal or irradiation at prophylactic dose
(typically 45 to 50 Gy by daily fractions of 1.8 to 2.0 Gy).
Though being more selective than older large fields
techniques irradiating the whole neck, the current tech-
nique still leads to the inclusion of large volumes of
potentially normal tissues because 55 to 82% of the cN0
patients are truly free of nodal involvement and bilateral
drainage is the rule in only 30 to 50% of individuals pre-
senting a tumour in a region with a known bilateral
drainage [3,11,16]. Moreover, it may lead to geographical
misses since 15 to 30% of the tumours drain in unpre-
dicted nodal basins [2,5,16,17].
The SLN dissection is a diagnostic surgical procedure
based on the injection of a radioactive nanocolloid in
the mucosa surrounding the tumour to map the first
drainage echelons on an individual basis. The preferen-
tial accumulation of the tracer in the SLN allows their
per-operative identification with a gamma-probe and
their exquisite surgical removal. One to four SLN may
be magnified for a given tumour, any other magnified
node being no first echelon [3,6,18]. The thorough
pathological analysis of these nodes predicts the nodal
stage of the neck with reported sensitivity, specificity
and negative predictive values ranging between 73–100%,
78–100% and 83–100%, respectively [3,4,6,7,9-11,17,19].
The sensitivity of the method is highest when a superse-
lective nodal dissection is performed (i.e. removal of the
level where the SLN is located) [3,5] and when performed
by an experienced team [9].
This SLN mapping concept is appealing for the head
and neck radiation oncologist because it may help to in-
dividually tailor the nodal prophylactic irradiation volume
in cN0 patients. Anyway, current surgical technique of
SLN localization with planar lymphoscintigraphy and
per-operative gamma-probe is not accurate enough for
radiotherapy planning. The recent development of a 3D
Lymphoscintigraphy (LS) based on Single Photon Emis-
sion Computed Tomography coupled with a Computed
Tomography (SPECT/CT) allows acquiring composite
images that could overcome this limitation by making
possible the accurate localization of the SLN [8,17,20,21].
The transfer of this diagnostic surgical method to the
technical context of radiotherapy, where no pathological
analysis is possible, first needs to be studied according to
a robust methodology. Indeed, key questions regarding
both the feasibility and the true reduction of treatment
volumes without increasing the risk of metachronous
relapses need to be answered before being tested in the
frame of a phase III randomized study.
A prospective phase I/II study was designed to test the
feasibility and the oncologic safety of the SLN mapping
method applied to the tailored prophylactic irradiation
of nodal stations in HNSCC patients being clinically N0.
We report here phase I results aimed at establishing the
feasibility and limitations of the SPECT/CT lymphos-
cintigraphy integration in the frame of RT specificities.
Ten patients were included and treated superselectively
according to individual data. A comparative planning with
selective prophylactic irradiation according to international
guidelines (IG) [15] was made for all patients to measure
potential dose reduction to normal tissues.
Methods
Patients and enrolment
Ten patients with non-operated pathologically proven
invasive HNSCC were prospectively invited to partici-
pate. Eligibility criteria included: age ≥ 18 years; referred
by oncology multidisciplinary team for primary radio-
therapy (with or without sensitization); no neo-adjuvant
chemotherapy or surgery; World Health Organization
performance status 0 or 1; any cT-stage primary tumour
located in the oral cavity, oropharynx, larynx (excepted
tumours strictly localized to the glottic plane) or hypo-
pharynx presenting a risk of nodal spread justifying a
prophylactic node irradiation; no macroscopic nodal or
distant metastasis spread as assessed by FDG-PET/CT
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and CT contrast agent injection. Nodes were deemed
cN0 if shortest diameter was ≤ 5 mm at retropharyngeal
level and ≤ 10 mm at any other level and/or exhibiting
no central necrosis. In dubious cases (high FDG uptake
or size in level 2 between 11 and 15 mm), a US with
FNAC had to be performed. Before registration, written
informed consent had to be given according to ICH/
GCP, and national/local regulations. Quality of Life (QoL)
assessment was performed the same day using EORTC
C30 and HN25 scales. Exclusion criteria were: pregnancy
or no active contraception for non-menopausal women;
HNSCC originating from nose, sinuses, oesophagus, saliv-
ary glands or nasopharynx; non-HNSCC histology; second
malignancy; previous history of cancer in the last 5 years
(excluding basal cell carcinoma of the skin and in situ
SCC of the cervix); known hypersensitivity to iodine or
nanocolloid injection; violated neck (i.e. previous surgery
or radiotherapy to the neck); any psychological, familial,
sociological or geographical condition potentially hamper-
ing compliance with the study protocol and follow-up
schedule. The study protocol and informed consent form
were reviewed and approved by the Ethics Committees
of CHU Dinant-Godinne and Clinique & Maternité
Sainte-Elisabeth on November 8th, 2012 (National Belgian
Reference Number: B039201215085).
Nanocolloid injection and SPECT/CT lymphoscintigraphy
Patients were simulated with their head blocked in a five
points thermoplastic mask according to our standard
protocol [22]. Within the next seven days, patients were
referred for SPECT/CT lymphoscintigraphy. Patients with
oral cavity and/or accessible oropharyngeal tumours
were injected without sedation in the Nuclear Medicine
department, the others during an endoscopy under a
short sedation in operating room [11]. Because surgical
expertise is of utmost importance [9], only two surgeons
having extensive experience with the SLN technique
performed all injections (ML for oropharyngeal and
oral cavity tumours; GL for laryngeal and hypopharyn-
geal tumours). 99mTc labelled human serum albumin
colloid (Nanocoll®, GE Healthcare, Diegem, Belgium)
was used as radioactive tracer (18,5-37 MBq in 1 ml)
and injected submucosally in four aliquots at one to five
millimetres from macroscopic tumour edges, according to
standard protocol used for surgical procedures [3,11].
Nanocoll® migration in SLN was verified with dynamic
planar lymphoscintigraphy for patients without sedation
or in the operating room with a hand-held kneed gamma
probe (NavigatorTM, RMD Instruments, LLC, Watertown,
MA, USA) before transfer to Nuclear Medicine depart-
ment when sedated.
SPECT/CT images were acquired on hybrid cameras,
either a Siemens SYMBIA T (Siemens, Erlangen, Germany)
or GE Discovery NM/CT 670 (GE Healthcare, Waukesha,
WI, USA) camera in uncontrolled position for the first
seven patients and for the next ones on a carbon tabletop
with RT mask positioned. SPECT acquisition parameters
were: 128 × 128 matrix, zoom 1, 2 detectors at 180°, 64
steps of 20 sec with the Siemens device or 60 steps of
15 sec for the GE one. Low-dose CT acquisition parameters
for the Siemens or the GE camera were respectively: slice
thickness 1.25 or 0.625 mm, 130 or 120 kV and dose modu-
lation with « Care Dose 4D » or modulation between 50
and 380 mAs. SPECT data were iteratively reconstructed
using CT data for attenuation correction.
Reconstructed images were transferred to a Mac Pro
under MacOSX 10.8.3 (Apple, Palo Alto, CA, USA) run-
ning the OsiriX MD v2.0.1 software (Pixmeo, Bernex,
Switzerland). Both the radiation oncologist and the
nuclear medicine specialist visually inspected fused
images for identification of all SLN that were recorded
in descending order of relative maximal activity and
anatomical localization according to standardized RT
nomenclature [15]. Only the four hottest nodes were
considered for radiotherapy planning; for patients exhibit-
ing more than four SLN, they were recorded as well but
not considered for planning.
Radiotherapy planning
Primary Gross Tumour Volume (GTVp) was delineated
according to our current practice on Eclipse Treatment
Planning System (Varian, Palo Alto, USA): CT-based,
modulated by clinical examination and MRI if available,
a five to 10 mm anisotropic margin being added to
generate the primary Clinical Target Volume (CTVp).
Defined OAR were: spinal cord, brainstem, parotids,
submandibular glands, swallowing muscles [23], oral
cavity for larynx/hypopharynx tumours, larynx for
oral/oropharyngeal tumours and Remaining Volume at
Risk (RVR) after final Planning Target Volume (PTV)
delineation (RVR = body – PTVtotal – all OAR). Two
different prophylactic nodes Clinical Target Volume
(CTVn) were defined: one “superselective” for treatment
purpose (real treatment plan) based on lymphoscinti-
graphy findings (CTVn-LS) selecting all node levels
containing the four hottest SLN [3,6,18]. The whole
level rather than the SLN alone had to be selected because
most of positive non-SLN nodes are located in the same
level [5]. Another one for comparison purpose (virtual
treatment plan) was planned based on international guide-
lines (CTVn-IG) with node levels selected according to
primary tumour location and extension (“selective”). For
putative patient(s) exhibiting no SLN, CTV considered for
treatment would have been the IG one. Various CTVs
were expanded by 4 mm to obtain the related PTVs.
Altered fractionation was prescribed if radiotherapy
alone was used (PTVp = 69 Gy in 30 fractions of 2.3 Gy;
PTVn = 55.5 Gy in 30 fractions of 1.85 Gy); conventional
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fractionation was prescribed if sensitizing cisplatinum or
cetuximab had to be used (PTVp = 70 Gy in 35 fractions
of 2.0 Gy; PTVn = 59.5 Gy in 35 fractions of 1.7 Gy).
Planning was performed with a Simultaneous Integrated
Boost technique (SIB) using volumetric arc modulated
radiotherapy (RapidArc, Varian, Palo Alto, CA, USA), dose
calculations being done with Analytical Anisotropic Algo-
rithm (AAA, Varian, Palo Alto, CA, USA). PTV coverage
had to comply with ICRU 83 recommendations [24] while
keeping D2% to spinal cord and brainstem below 45 and
50 Gy, respectively. Maximal optimization was required
on all defined OAR. RVR dose was constrained through
the use of concentric rings around the PTV. To avoid any
bias, the same dosimetrist optimized both plans at the
same time, always starting with the LS-one.
Statistics
R (version 2.15.1, The R Foundation for Statistical
Computing, Vienna, Austria) was used for statistical
analysis. As normality could not be assumed, median
and interquartile range were computed and differences
between planning methods were analyzed with Wilcoxon
signed rank test with continuity correction. P-values
less than .05 were considered statistically significant.
Results
Patients
Ten patients fulfilling inclusion criteria accepted to par-
ticipate and signed informed consent between 9 January
and 24 June 2013. There were nine males and one female;
age ranged from 43 to 89 years (mean 63). Tumours loca-
tions and cT-stages: seven in the larynx (three T2 and four
T3, all with supra- and/or sub-glottic extension and hence,
increased risk of nodal dissemination); two in the orophar-
ynx (both T2) and one in the oral cavity (small T4 of the
hard palate mucosa infiltrating the underlying bone). All
tumors were judged eligible by the surgeons for peri-
tumoral nanocolloid injection. Seven patients were treated
by altered fractionation, three by conventional fraction-
ation (one with concomitant three-weekly cisplatinum
and two with weekly cetuximab). All were treated accord-
ing to LS volumes. All ended their radiotherapy course
within the prescribed overall treatment time.
Nanocolloid migration and target volume selection
Nanocoll® migration was observed in all patients either
on planar LS or with hand-held gamma probe. SPECT/
CT migration was observed in all patients except patient
6 (larynx, T3 – Figure 1) where tumour burden hid the
SLN activity, detected subsequently by gamma probe in
the homolateral level 3. On average, 2.9 nodes were
detected per patient: one in two patients, two in three
patients, three in two patients, four in one patient, five
in one patient and six in one patient (Table 1). CTVn-LS
volumes were selected based on the four hottest nodes
since any supplementary highlighted node is not consid-
ered as a first echelon [3,6,18]. For patients 4 and 7 the
localization on the planning CT was difficult because of
patient position differences between SPECT/CT and plan-
ning CT (Figure 2). From patient 8 onwards, SPECT/CT
were acquired with patient lying on a flat carbon couch
and immobilized with its radiotherapy thermoplastic mask
to allow easier accurate SLN localizations.
The CTVn-LS volume was totally encompassed by
CTVn-IG volumes except in one case (patient 1) where
migration in homolateral retrostyloid region was unpre-
dicted by IG (Table 1). LS volumes were systematically
smaller than related IG ones, by a factor of two on aver-
age (P = 0.006) (Figure 3). As example, the differences in
CTVn selections are depicted for patient 2 in Figure 4.
Dosimetry
CTVn-LS and CTVn-IG were correctly covered in all
patients with lower D98% of 96.6 and 96.5%, respectively
and lower D95% of 98.9 and 97.8%, respectively. The
same holds true for the PTVs except for patient 4 due to
build-up effect in the level 6 where the PTV expanded
in the air anteriorly (Table 2).
Doses delivered to OAR were significantly reduced in LS
plans, except for the spinal cord and the low pharyngeal
constrictor muscle (LPC) (Table 3). Regarding the spinal
cord, the integral dose was in all cases reduced. The ab-
sence of statistical difference for LPC is related to primary
tumours locations, being the larynx for seven patients.
Discussion
In this prospective phase I study, we demonstrate the
potential of SPECT/CT-based LS of SLN for non-operated
cN0 HNSCC patients eligible for definitive irradiation.
It allows individualizing the superselective selection of
prophylactic nodal target volume while significantly re-
ducing normal tissues irradiation. Two potential pitfalls
were also highlighted. The first concerns small inaccur-
acies in SLN localization when patient position is not con-
trolled, which can be overcome by acquiring SPECT/CT
with radiotherapy thermoplastic mask on a flat carbon
couch. The second relates to non-migration of colloid into
SLN. The incidence is low, ranging from 0% [6,11] to 7%
[10]. In this case, we recommend selecting target volume
based on IG rather than avoiding prophylactic nodal
irradiation since it may be due either to node hilus
blockage by tumour cells or delay in migration justify-
ing late acquisition on SPECT/CT [6,20]. Rarely, the
SLN that may be hidden on SPECT/CT images by the
intense activity around the tumour may be detected by
the unidirectional handheld gamma probe [17]. This is also
documented in floor of mouth tumours where gamma
probe may even be inefficient [2,10]. It happened for patient
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6 where SPECT-CT did not image any SLN while the
unidirectional handheld probe could detect one in level
3, in the close vicinity of the larynx tumour.
The integration of SPECT/CT LS information to radio-
therapy plans is quite recent with two papers reporting its
potential interest for prostate [25] and breast [26] cancers
treatment. In a prospective series of 20 prostate cancer
patients with a nodal risk ≥ 20%, SPECT/CT acquired
90 minutes after injection of nanocolloid in prostate
magnified 27 SLN outside of standard CTV in 14 patients.
After exclusion of paraaortic and inguinal nodes, there
were still nine pararectal nodes magnified leading to a
modification of CTV in six patients (30%) [25]. In breast
cancer, standard tangential fields imply unnecessary irradi-
ation of arm draining lymph nodes, increasing the risk for
lymphedema. A prospective study on 28 patients aimed at
identifying these nodes with SPECT/CT after injection of
nanocolloid in the arm. The modification of standard
fields to block the 57% of nodes included in the stand-
ard fields, led to a reduction of mean dose to these
nodes from 23.6 to 7.7 Gy, without compromising tar-
get irradiation. No patient developed lymphedema [26].
Figure 1 Axial SPECT/CT slice, patient 6. No apparent migration is depicted in level 3 left, probably due to intense activity in neighbouring tumour.
Table 1 Tumour details per patient
Patient # 1 2 3 4 5 6 7 8 9 10 Median
Localization Oropharynx Larynx Oral cavity Larynx Oropharynx Larynx Larynx Larynx Larynx Larynx
Laterality L L L L L B B R R B
cT-stage 2 3 4 3 2 3 2 2 3 2
Number of SLN 4 3 1 5 2 1 2 3 2 6
CTVn-LS selection
Levels left 2, 3 2, 3 - 3, 6 2 3 3 - - 3
Levels right RS - 2 3, 6 2 - 3 2-4 2-4 3,4
Volume (cc) 141.8 80.3 119.8 144.2 74.8 87.8 67.5 88.4 101.2 96.7 92.6
Volume PTVn-LS (cc) 287.5 191.5 267.6 277.2 204.7 196.8 198.9 216.1 245.8 243.5 229.8
CTVn-IG selection
Levels left 2 - 4 2 - 4 1b - 4 2-4, 6 2-4 2-4 2-4 2-4 2-4 2-4, 6
Levels right 2 - 4 2 - 4 1b - 4 2-4, 6 2-4 2-4 2-4 2-4 2-4 2-4, 6
Volume (cc) 223.0 160.8 225.0 219.3 154.8 215.7 118.7 195.3 179.6 209.0 202.2
Volume PTVn-IG (cc) 451.4 405.3 508.4 447.0 404.1 465.6 330.2 476.6 428.7 492.2 449.2
SLN = sentinel lymph node; L = left; R = right; B = bilateral; RS = retrostyloid.
Volumes selection and measurements are based either on lymphoscintigraphy (LS) or international guidelines (IG). Median volumes are reported in last column.
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Figure 2 Inaccuracy in node level localization due to variations in head position. For patient 7, the correct localization of the sentinel node
on simulation CT (B) was based on vascular calcifications on SPECT/CT (A) (white arrows). The discordance between SPECT/CT (level 2) and
simulation CT (level 3) is due to uncontrolled position of the head for SPECT/CT acquisition and subsequent relative position of hyoid bone
(dotted red line, C and D).
Figure 3 Measured target volumes for the different patients, based on international guidelines (IG) or lymphoscintigraphy (LS). Respective
median values are written between parentheses.
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In the head and neck area, this is the first time that
SPECT/CT LS is used to individualize TV selection.
Nevertheless, some key questions still must be answered,
oncological safety being the most important. Patient
recruitment is maintained through prolongation in a
phase II study (44 patients in total) aiming at establishing
the true risk of relapse outside of TV at two years. In sur-
gical series, skip metastases (i.e. metastases in non SLN)
or metachronous nodal relapse rates are on average of the
order of 5% (range [3–10%]) [3,6,12,13]. In surgical cases,
a positive SLN leads to complimentary neck dissection.
Additional infiltrated non-SLN nodes are mainly located
in the same level [5]. This is the safety reason why we
decided to include the full level(s) in the CTVn rather
than the SLN alone. The risk for occult nodal metastases
outside of involved levels is 7% of all positive cases, which
sets the global risk at less than 2% of all patients [5]. This
risk is sufficiently negligible to avoid any further enlarge-
ment of the CTVn. Another key question relates to the
limitation of the highlighted nodes to four since any
supplementary node is not considered as first echelon
[3,6,18]. Further follow-up will learn us if potentially
Figure 4 Impact of lymphoscintigraphy on volumes selection and dose distribution for patient 2. Left: PTV based on international guidelines
projected on Digitally Reconstructed Radiographies (DRR) and correlated 3D dose distribution. Centre: SPECT/CT coronal view depicting 1 node caudally
in level 2 left and 2 other ones in level 3 left. Right: PTV selection based on lymphoscintigraphy projected on DRR and correlated 3D dose distribution.
Table 2 Target volumes coverage for plans based on either lymphoscintigraphy (LS) volumes or international
guidelines (IG) ones
Patient # 1 2 3 4 5 6 7 8 9 10 Median P-value
CTVn-LS doses (%)
D95% 100.2 103.7 100.0 99.2 100.9 102.9 99.8 98.9 99.8 99.5 99.91 0.232
D98% 98.7 102.2 98.9 96.6 99.8 101.7 99.3 98.4 99.3 98.6 99.10 0.284
Dmean 111.4 113.9 117.7 107.1 118.7 115.0 107.4 108.5 107.2 108.3 109.91 0.006
PTVn-LS doses (%)
D95% 98.7 100.5 98.4 90.9 100.4 101.5 98.7 98.7 99.1 98.9 98.83 0.059
D98% 97.5 97.5 88.5 80.0 99.1 100.2 96.9 98.2 98.4 98.2 97.84 0.185
Dmean 111.0 111.8 114.2 102.9 117.1 114.1 106.1 108.5 106.3 106.8 109.73 0.006
CTVn-IG doses (%)
D95% 98.2 99.5 100.0 97.8 100.9 101.2 100.5 99.6 99.3 100.2 99.82 -
D98% 96.6 98.3 99.3 96.5 99.3 100.2 99.8 98.7 98.6 99.5 99.01 -
Dmean 110.1 107.1 110.8 105.5 112.4 109.6 106.3 105.8 104.7 106.5 106.77 -
PTVn-IG doses (%)
D95% 96.6 96.5 98.7 90.4 98.9 99.2 98.6 98.9 98.7 99.1 98.74 -
D98% 88.1 94.1 95.1 82.0 96.6 97.3 95.5 98.0 98.0 97.3 96.04 -
Dmean 109.2 105.2 108.6 101.8 111.0 108.4 105.2 105.4 104.3 104.7 105.32 -
CTVn = prophylactic nodes clinical target volume; PTVn = prophylactic nodes planning target volume; D95% = dose received by 95% of the volume; D98% = dose
received by 98% of the volume; Dmean = mean dose.
P-values for statistical differences for LS values compared to IG ones are reported in last column; level of significance is set at 0.05.
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relapsing patients will do so in highlighted nodes not
included in the CTVn-LS.
A randomized phase III study could be initiated if
nodal relapse outside of TV is < 10%. Other key questions
like impact on overall survival and quality of life should
also be answered in the future to confirm the potential
added value of this technique.
Conclusions
In cN0 HNSCC patients, individualized superselective
prophylactic irradiation of nodal TV was investigated with
use of SLN SPECT/CT lymphoscintigraphy information.
This phase I study on 10 patients demonstrated the feasi-
bility and the possible pitfalls of the technique. Compared
to selective CTVn selection according to international
guidelines, the PTV was reduced by a factor of two. Using
VMAT planning, a significant decrease in normal tissues
irradiation could be achieved. The safety must be con-
firmed by the ongoing phase II study.
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Table 3 Comparative dosimetry after planning based on
lymphoscintigraphy (LS) or international guidelines (IG)
volumes
LS IG P-value
Nervous structures
Spinal cord D2% (Gy) 41.7 43.4 0.083
Brainstem D2% (Gy) 4.2 23.7 0.013
Salivary glands
Left parotid Dmean (Gy) 4.2 25.0 0.006
Right parotid Dmean (Gy) 10.9 25.4 0.006
Left submand Dmean (Gy) 22.6 46.9 0.009
Right submand Dmean (Gy) 27.4 42.7 0.014
Swallowing muscles
SPC Dmean (Gy) 22.3 41.2 0.009
MPC Dmean (Gy) 45.1 54.6 0.041
LPC Dmean (Gy) 55.4 56.4 0.154
UES Dmean (Gy) 39.8 54.3 0.006
Oesophagus Dmean (Gy) 9.6 43.6 0.006
Oral cavity Dmean (Gy) 15.0 20.3 0.024
RVR volume at Dproph (cc) 63.7 108.4 0.006
D2% = dose received by 2% of the volume; Dmean = mean dose; Submand =
submandibular gland; SPC = superior pharyngeal constrictor muscle;
MPC =middle pharyngeal constrictor muscle; LPC = low pharyngeal
constrictor muscle; UES = upper oesophageal sphincter.
Median D2% for nervous structures; median Dmean for salivary glands,
swallowing structures and oral cavity and median volume of remaining
volume at risk (RVR) treated at prophylactic dose (Dproph) are reported.
P-values for statistical comparison of differences are reported in last
column; significant values are written in bold.
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